BamSEC and AlphaSense Join Forces
Learn More

Salix Pharmaceuticals Ltd

Formerly NASDAQ: SLXP
Search in Documents
Key Exhibits
External Links

Plans of Reorganization, Merger, Acquisition or Similar Filter

EX-2.1
from 8-K 4 pages Amendment No. 1 to Agreement and Plan of Merger
12/34/56
EX-2.1
from 8-K 93 pages Agreement and Plan of Merger by and Among Valeant Pharmaceuticals International, Sun Merger Sub, Inc., Valeant Pharmaceuticals International, Inc. and Salix Pharmaceuticals, Ltd. Dated as of February 20, 2015
12/34/56
EX-2.1
from SC TO-C 93 pages Agreement and Plan of Merger by and Among Valeant Pharmaceuticals International, Sun Merger Sub, Inc., Valeant Pharmaceuticals International, Inc. and Salix Pharmaceuticals, Ltd. Dated as of February 20, 2015
12/34/56
EX-2.1
from 8-K 367 pages Agreement and Plan of Merger and Reorganization by and Among Cosmo Pharmaceuticals S.P.A., Cosmo Technologies Limited, Sangiovese, LLC, and Salix Pharmaceuticals, Ltd. Dated as of July 8, 2014
12/34/56
EX-2.1
from 425 367 pages Agreement and Plan of Merger and Reorganization by and Among Cosmo Pharmaceuticals S.P.A., Cosmo Technologies Limited, Sangiovese, LLC, and Salix Pharmaceuticals, Ltd. Dated as of July 8, 2014
12/34/56
EX-2
from SC 13D 52 pages Commitment Letter
12/34/56
EX-2.2
from 8-K 22 pages Introduction
12/34/56
EX-2.2
from SC TO-C 22 pages Introduction
12/34/56
EX-2.1
from SC TO-C 98 pages Agreement and Plan of Merger Dated as of November 7, 2013 Among Salix Pharmaceuticals, Ltd., Salix Pharmaceuticals, Inc. (Solely for Purposes of Section 2.1(b) and Sections 4.3(a), (D) and (E)), Willow Acquisition Sub Corporation and Santarus, Inc
12/34/56
EX-2.1
from 8-K 98 pages Agreement and Plan of Merger Dated as of November 7, 2013 Among Salix Pharmaceuticals, Ltd., Salix Pharmaceuticals, Inc. (Solely for Purposes of Section 2.1(b) and Sections 4.3(a), (D) and (E)), Willow Acquisition Sub Corporation and Santarus, Inc
12/34/56
EX-2.5
from 10-K 88 pages Portions of This Exhibit Marked [*] Are Omitted and Are Requested to Be Treated Confidentially
12/34/56
EX-2.4
from 10-K 65 pages Portions of This Exhibit Marked [*] Are Omitted and Are Requested to Be Treated Confidentially
12/34/56
EX-2.1
from 8-K 75 pages Agreement and Plan of Merger by and Among Salix Pharmaceuticals, Ltd. Inkine Pharmaceutical Company, Inc. and Metal Acquisition Corp. Dated as of June 23, 2005
12/34/56
EX-2.1
from 425 75 pages Agreement and Plan of Merger by and Among Salix Pharmaceuticals, Ltd. Inkine Pharmaceutical Company, Inc. and Metal Acquisition Corp. Dated as of June 23, 2005
12/34/56
EX-2.2
from 10-Q 40 pages Portions of This Exhibit Marked [*] Are Omitted and Are Requested to Be Treated Confidentially. Asset Purchase Agreement Article 1 Definitions and References
12/34/56
EX-2
from SC 14D9 2 pages Salix Pharmaceuticals Board Unanimously Recommends Rejection of Axcan’s Unsolicited Tender Offer
12/34/56
EX-2.1
from S-3 1 page Certificate of Domestication
12/34/56
EX-2.1
from S-4 1 page Certificate of Domestication
12/34/56